Literature DB >> 16714568

Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection.

Michelle A Parent1, Lindsey B Wilhelm, Lawrence W Kummer, Frank M Szaba, Isis K Mullarky, Stephen T Smiley.   

Abstract

Pulmonary infection by Yersinia pestis causes pneumonic plague, a rapidly progressing and often fatal disease. To aid the development of safe and effective pneumonic plague vaccines, we are deciphering mechanisms used by the immune system to protect against lethal pulmonary Y. pestis infection. In murine pneumonic plague models, passive transfer of convalescent-phase sera confers protection, as does active vaccination with live Y. pestis. Here, we demonstrate that protection by either protocol relies upon both gamma interferon (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) cytokines classically associated with type 1 cellular immunity. In both protocols, abrogating IFN-gamma or TNF-alpha activity significantly decreases survival and increases the bacterial burden in pulmonary, splenic, and hepatic tissues. Neutralization of either cytokine also counteracts challenge-induced, vaccination-dependent upregulation of nitric oxide synthase 2 (NOS2). Moreover, genetic depletion of NOS2 suppresses protection conferred by serotherapy. We conclude that IFN-gamma, TNF-alpha, and NOS2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Y. pestis challenge. These observations strongly suggest that plague vaccines should strive to maximally prime both cellular and humoral immunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16714568      PMCID: PMC1479272          DOI: 10.1128/IAI.00185-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

Review 1.  Antibody regulation of Tcell immunity: implications for vaccine strategies against intracellular pathogens.

Authors:  Joseph U Igietseme; Francis O Eko; Qing He; Carolyn M Black
Journal:  Expert Rev Vaccines       Date:  2004-02       Impact factor: 5.217

Review 2.  Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen).

Authors:  Robert R Brubaker
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

3.  The Bordetella bronchiseptica type III secretion system inhibits gamma interferon production that is required for efficient antibody-mediated bacterial clearance.

Authors:  Mylisa R Pilione; Eric T Harvill
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

4.  Multidrug resistance in Yersinia pestis mediated by a transferable plasmid.

Authors:  M Galimand; A Guiyoule; G Gerbaud; B Rasoamanana; S Chanteau; E Carniel; P Courvalin
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

Review 5.  Plague immunization. I. Past and present trends.

Authors:  K F Meyer; D C Cavanaugh; P J Bartelloni; J D Marshall
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

6.  Plague bacillus: survival within host phagocytes.

Authors:  W A Janssen; M J Surgalla
Journal:  Science       Date:  1969-02-28       Impact factor: 47.728

7.  Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice.

Authors:  M H Kaplan; Y L Sun; T Hoey; M J Grusby
Journal:  Nature       Date:  1996-07-11       Impact factor: 49.962

8.  Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha.

Authors:  R Nakajima; R R Brubaker
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

9.  Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice.

Authors:  G W Anderson; D G Heath; C R Bolt; S L Welkos; A M Friedlander
Journal:  Am J Trop Med Hyg       Date:  1998-06       Impact factor: 2.345

10.  Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity.

Authors:  Florian Woelbing; Susanna Lopez Kostka; Katharina Moelle; Yasmine Belkaid; Cord Sunderkoetter; Sjef Verbeek; Ari Waisman; Axel P Nigg; Juergen Knop; Mark C Udey; Esther von Stebut
Journal:  J Exp Med       Date:  2006-01-17       Impact factor: 14.307

View more
  56 in total

1.  Mathematical relationship between cytokine concentrations and pathogen levels during infection.

Authors:  Yue Zhang; James B Bliska
Journal:  Cytokine       Date:  2010-11-18       Impact factor: 3.861

2.  Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.

Authors:  Henry S Heine; Arnold Louie; Jeffrey J Adamovicz; Kei Amemiya; Randy L Fast; Lynda Miller; Steven M Opal; John Palardy; Nicolas A Parejo; Fritz Sörgel; Martina Kinzig-Schippers; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

3.  Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection.

Authors:  Alexander V Philipovskiy; Stephen T Smiley
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

Review 4.  Interaction between Yersinia pestis and the host immune system.

Authors:  Bei Li; Ruifu Yang
Journal:  Infect Immun       Date:  2008-02-04       Impact factor: 3.441

5.  A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Xinghong Yang; Sarah Golden; Catharine M Bosio; Kathryn Crist; Todd Becker; Massimo Maddaloni; David W Pascual
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

6.  Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.

Authors:  Melissa C Hanson; Monica P Crespo; Wuhbet Abraham; Kelly D Moynihan; Gregory L Szeto; Stephanie H Chen; Mariane B Melo; Stefanie Mueller; Darrell J Irvine
Journal:  J Clin Invest       Date:  2015-05-04       Impact factor: 14.808

7.  An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Richard Bowen; Xinghong Yang; Kathryn Crist; Sarah Golden; Massimo Maddaloni; David W Pascual
Journal:  Vaccine       Date:  2008-10-26       Impact factor: 3.641

8.  Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague.

Authors:  Wei Sun; Kenneth L Roland; Xiaoying Kuang; Christine G Branger; Roy Curtiss
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

9.  O antigen allows B. parapertussis to evade B. pertussis vaccine-induced immunity by blocking binding and functions of cross-reactive antibodies.

Authors:  Xuqing Zhang; Maria Eugenia Rodríguez; Eric T Harvill
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

10.  The role of relA and spoT in Yersinia pestis KIM5 pathogenicity.

Authors:  Wei Sun; Kenneth L Roland; Christine G Branger; Xiaoying Kuang; Roy Curtiss
Journal:  PLoS One       Date:  2009-08-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.